Schizophrenia
Olanzapine offers benefits in Asian patients with schizophrenia
Published in Medical Letter on the CDC and FDA, July 9th, 2006
In a recently published article, scientists in Taiwan conducted a study "to examine clinical outcomes in Asian patients with schizophrenia receiving monotherapy with olanzapine, risperidone, or typical antipsychotics in naturalistic settings. In this report, data from the first 12 months of the prospective, observational, three-year Intercontinental Schizophrenia Outpatient Health Outcomes study are presented for patients from participating Asian countries (Korea, Taiwan, and Malaysia) who were started on, or switched to, monotherapy with olanzapine (n=484),...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Food-Borne Illness
Salmonella Heidelberg outbreaks in U.S. traced to poultry and eggs - Food-Borne Illness
Aging of cheese made from unpasteurized milk does not eliminate Escherichia coli O157:H7 - HIV/AIDS Diagnosis
HIV RNA testing improves diagnosis of HIV infection in high-risk patients - Hepatitis E Virus
Locally acquired hepatitis E virus infection in Texas reported - Sexual & Reproductive Health
High-risk behaviors linked to Viagra use among men who have sex with men - Acute Myelogenous Leukemia
CuraGen and TopoTarget announce NCI-sponsored Phase II clinical trial with PXD101 for AML - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
